Evidence map›Paper›PMID 29983236›Full record

ArticleAnnals of epidemiology2018

The prevalence of pre-exposure prophylaxis use and the pre-exposure prophylaxis-to-need ratio in the fourth quarter of 2017, United States.

Aaron J Siegler, Farah Mouhanna, Robertino Mera Giler, Kevin Weiss, Elizabeth Pembleton, Jodie Guest, Jeb Jones, Amanda Castel, Howa Yeung, Michael Kramer and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Annals of epidemiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 270 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
270citing papers in PubMed, 3 pooled it
27.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

270 citing papers in PubMed, 3 syntheses or guidelines pooled it, 422 citations in OpenAlex.

  1. Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV - CDC Recommendations, United States, 2025.MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports · 2025
    Guideline
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Trends in Persons Prescribed HIV Postexposure Prophylaxis in the United States, 2015-2023.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
    Article
  17. Article
  18. The 2025 Centers for Disease Control and Prevention Nonoccupational HIV Postexposure Prophylaxis Guidelines: Updated Regimens and Remaining Questions.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
    Article
  19. Article
  20. Assessing Non-Oral PrEP Alternatives Among Young Black Women in the Southern USA.Journal of racial and ethnic health disparities · 2026
    Article

210 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Aaron J SieglerDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA. Electronic address: asiegle@emory.edu.
Farah MouhannaDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA; Department of Epidemiology and Biostatistics, Milken Institute School of Public Health, The George Washington University, Washington, DC.
Robertino Mera GilerPharmacovigilance & Epidemiology, Gilead Sciences, Foster City, CA.
Kevin WeissDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA.
Elizabeth PembletonDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA.
Jodie GuestDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA.
Jeb JonesDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA.
Amanda CastelDepartment of Epidemiology and Biostatistics, Milken Institute School of Public Health, The George Washington University, Washington, DC.
Howa YeungDepartment of Family and Preventive Medicine, School of Medicine, Emory University, Atlanta, GA.
Michael KramerDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA.
Scott McCallisterPharmacovigilance & Epidemiology, Gilead Sciences, Foster City, CA.
Patrick S SullivanDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA.
Emory University · USGilead Sciences (United States) · USMilken Institute · US

Funding

Implementing a Maternal health and PRegnancy Outcomes Vision for Everyone (IMPROVE)UL1TR002378 · NCATS · EMORY UNIVERSITY · PI Andres J Garcia, Elizabeth O. Ofili · 2017 to 2026
$92.1M
Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Carlos del Rio · 2002 to 2026
$74.0M
The UNC/Emory Center for Innovative Technology (iTech) across the prevention and care continuumU19HD089881 · NICHD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HIGHTOW-WEIDMAN, LISA B, SULLIVAN, PATRICK SEAN · 2016 to 2022
$35.8M
Institutional Career Development CoreKL2TR002381 · NCATS · EMORY UNIVERSITY · PI HENRY M BLUMBERG, Anandi Nayan Sheth · 2017 to 2026
$14.1M
Making it last: A randomized, controlled trial of a home care system to promote persistence in PrEP careR01MH114692 · NIMH · EMORY UNIVERSITY · PI MAYER, KENNETH H, SIEGLER, AARON JULIUS · 2017 to 2021
$5.8M
NCATS NIH HHS KL2 TR002381NCATS NIH HHS UL1 TR002378NIAID NIH HHS P30 AI050409NICHD NIH HHS U19 HD089881NIMH NIH HHS R01 MH114692
6 · The paper itself

Abstract

purposeThe number of individuals who have started a regimen for HIV pre-exposure prophylaxis (PrEP) in the United States is not well characterized but has been on the rise since 2012. This analysis assesses the distribution of PrEP use nationally and among subgroups.

methodsA validated algorithm quantifying tenofovir disoproxil fumarate/emtricitabine for PrEP in the United States was applied to a national prescription database to determine the quarterly prevalence of PrEP use. HIV diagnoses from 2016 were used as an epidemiological proxy for PrEP need. The PrEP-to-need ratio (PnR) was defined as the number of PrEP users divided by new HIV diagnoses.

resultsA total of 70,395 individuals used PrEP in the fourth quarter of 2017: 67,166 males and 3229 females. Nationally, prevalence of PrEP use was 26/100,000 (range across states per 100,000 [RAS/100k]: 4-73) and the PnR was 1.8 (RAS: 0.5-6.6). Prevalence of PrEP use among males and females, respectively, was 50/100,000 and 2/100,000 (RAS/100k: 7-143 and 0.3-7) and PnR was 2.1 and 0.4 (RAS: 0.6-7.1 and 0.1-4.0). Prevalence of PrEP use was lowest among individuals aged less than or equal to 24 and more than or equal to 55 years (15/100,000 and 6/100,000, RAS/100k: 1-45 and 0.4-14), with PnR 0.9 and 1.5 (RAS: 0.2-5.6 and 0.3-7.0). The Northeast had the highest PnR (3.3); the South had the lowest (1.0). States with Medicaid expansion had more than double the PnR than states without expansion.

conclusionsAvailable data suggest that females, individuals aged less than or equal to 24 years and residents of the South had lower levels of PrEP use relative to epidemic need. These results are ecological, and misclassification may attenuate results. PnR is useful for future assessments of HIV prevention strategy uptake.

Indexed as

AdolescentAdultAge DistributionAnti-HIV AgentsCross-Sectional StudiesEmtricitabine, Tenofovir Disoproxil Fumarate Drug CombinationFemaleHIV InfectionsHumansMaleMiddle AgedPre-Exposure ProphylaxisPrescriptionsPrevalenceUnited StatesYoung AdultAnti-HIV AgentsEmtricitabine, Tenofovir Disoproxil Fumarate Drug CombinationHIVPre-exposure prophylaxisPrevention

Identifiers

PMID29983236
PMCPMC6286209
OpenAlexW2808046551

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.